Engineers Gate Manager LP Vertex Pharmaceuticals Inc Transaction History

Engineers Gate Manager LP

$4.86 Billion
Q3 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$392.81 - $485.53 $346,065 - $427,751	881 Added 7.05%	13,386 $6.27 Million
Q1 2024 May 15, 2024	BUY	$407.69 - $446.08 $1.99 Million - $2.18 Million	4,886 Added 64.13%	12,505 $5.23 Million
Q4 2023 Feb 14, 2024	SELL	$343.0 - $410.68 $375,928 - $450,105	-1,096 Reduced 12.58%	7,619 $3.1 Million
Q3 2023 Nov 14, 2023	BUY	$338.18 - $362.46 $1.83 Million - $1.97 Million	5,422 Added 164.65%	8,715 $3.03 Million
Q2 2023 Aug 14, 2023	BUY	$314.42 - $351.91 $244,933 - $274,137	779 Added 30.99%	3,293 $1.16 Million
Q1 2023 May 15, 2023	SELL	$283.23 - $323.1 $7.87 Million - $8.98 Million	-27,783 Reduced 91.7%	2,514 $792,000
Q4 2022 Feb 14, 2023	BUY	$285.76 - $321.48 $7.99 Million - $8.99 Million	27,959 Added 1195.85%	30,297 $8.75 Million
Q3 2022 Nov 14, 2022	SELL	$273.83 - $305.53 $759,330 - $847,234	-2,773 Reduced 54.26%	2,338 $677,000
Q2 2022 Aug 15, 2022	SELL	$234.96 - $292.55 $505,868 - $629,860	-2,153 Reduced 29.64%	5,111 $1.44 Million
Q1 2022 May 16, 2022	SELL	$221.42 - $260.97 $592,962 - $698,877	-2,678 Reduced 26.94%	7,264 $1.9 Million
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $5.98 Million - $7.55 Million	-33,802 Reduced 77.27%	9,942 $2.18 Million
Q3 2021 Nov 15, 2021	BUY	$181.39 - $202.99 $3.06 Million - $3.42 Million	16,851 Added 62.66%	43,744 $7.94 Million
Q2 2021 Aug 16, 2021	BUY	$187.49 - $221.1 $4.56 Million - $5.37 Million	24,300 Added 937.14%	26,893 $5.42 Million
Q1 2021 May 17, 2021	BUY	$207.02 - $241.31 $2,898 - $3,378	14 Added 0.54%	2,593 $557,000
Q4 2020 Feb 16, 2021	SELL	$207.01 - $276.09 $1.91 Million - $2.55 Million	-9,241 Reduced 78.18%	2,579 $610,000
Q3 2020 Nov 16, 2020	BUY	$255.65 - $303.1 $2.41 Million - $2.85 Million	9,410 Added 390.46%	11,820 $3.22 Million
Q2 2020 Aug 17, 2020	SELL	$225.48 - $295.8 $4,058 - $5,324	-18 Reduced 0.74%	2,410 $700,000
Q1 2020 May 15, 2020	SELL	$199.77 - $247.81 $2.59 Million - $3.21 Million	-12,957 Reduced 84.22%	2,428 $578,000
Q4 2019 Feb 14, 2020	BUY	$166.71 - $223.91 $1.94 Million - $2.61 Million	11,654 Added 312.36%	15,385 $3.37 Million
Q3 2019 Nov 14, 2019	SELL	$166.23 - $187.09 $1.86 Million - $2.09 Million	-11,172 Reduced 74.96%	3,731 $632,000
Q2 2019 Aug 14, 2019	BUY	$164.61 - $190.37 $2.45 Million - $2.84 Million	14,903 New	14,903 $2.73 Million

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

Capital World Investors Los Angeles, CA

26.8M
Shares

$12.5 Billion
1.99% of portfolio
Vanguard Group Inc Valley Forge, PA

23.2M
Shares

$10.8 Billion
0.2% of portfolio
Black Rock Inc. New York, NY

21.3M
Shares

$9.9 Billion
0.23% of portfolio
State Street Corp Boston, MA

11.8M
Shares

$5.49 Billion
0.23% of portfolio
Capital Research Global Investors Los Angeles, CA

9M
Shares

$4.18 Billion
0.9% of portfolio

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

News

Stay updated on Engineers Gate Manager LP with notifications on news.

Account